Notably, the introduction of novel agents has transformed the treatment landscape for MCL; in particular, BTKi have demonstrated significant efficacy, providing a targeted therapy for MCL patients [25,26,27,28]. The gene discussed is IBTK; the disease is mantle cell lymphoma.